Purpose of Review In this paper, we summarize prior studies that have used Mendelian randomization (MR) methods to study the effects of exposures, lifestyle factors, physical traits, and/or biomarkers on cancer risk in humans. Many such risk factors have been associated with cancer risk in observational studies, and the MR approach can be used to provide evidence as to whether these associations represent causal relationships. MR methods require a risk factor of interest to have known genetic determinants that can be used as proxies for the risk factor (i.e., "instrumental variables" or IVs), and these can be used to obtain an effect estimate that, under certain assumptions, is not prone to bias caused by unobserved confounding or reverse causality. This review seeks to describe how MR studies have contributed to our understanding of cancer causation. Recent Findings We searched the published literature and identified 76 MR studies of cancer risk published prior to October 31, 2017. Risk factors commonly studied included alcohol consumption, vitamin D, anthropometric traits, telomere length, lipid traits, glycemic traits, and markers of inflammation. Risk factors showing compelling evidence of a causal association with risk for at least one cancer type include alcohol consumption (for head/neck and colorectal), adult body mass index (increases risk for multiple cancers, but decreases risk for breast), height (increases risk for breast, colorectal, and lung; decreases risk for esophageal), telomere length (increases risk for lung adenocarcinoma, melanoma, renal cell carcinoma, glioma, B-cell lymphoma subtypes, chronic lymphocytic leukemia, and neuroblastoma), and hormonal factors (affects risk for sex steroid-sensitive cancers). Summary This review highlights alcohol consumption, body mass index, height, telomere length, and the hormonal exposures as factors likely to contribute to cancer causation. This review also highlights the need to study specific cancer types, ideally subtypes, as the effects of risk factors can be heterogeneous across cancer types. As consortia-based genome-wide association studies increase in sample size and analytical methods for MR continue to become more sophisticated, MR will become an increasingly powerful tool for understanding cancer causation.
Introduction
There are many risk factors with well-established associations with cancer risk, but for most, it is unclear whether a causal relationship underlies the observed association. While cancer prevention trials (i.e., randomized controlled trials) have been used to estimate the causal effects of modulating several specific risk factors (e.g., aspirin and chronic inflammation), it is not feasible to study most risk factors in this way due to lack of effective interventions, high costs, and/or ethical reasons.
For a subset of cancer-associated risk factors, it is possible to gain insights into causality using Mendelian randomization (MR). MR is a method used to test or estimate a causal effect of an exposure on a disease outcome using known genetic determinants of the exposure. These genetic determinants are used as instrumental variables (IVs) to determine whether an observed exposure-disease association may be due to a causal relationship, as opposed to unobserved confounding or reverse causation.
A valid MR analysis requires that the IVs are (1) associated with the exposure, (2) independent of factors that confound the exposure-outcome relationship; and (3) independent of the outcome, given the exposure and confounders of the exposure-outcome relationship. These assumptions are coded on the following directed acyclic graph ( Fig. 1) showing an exposure (X), and outcome (Y), and multiple valid IVs (G 1 , G 2 , …, G n ). To make causal inference for the effect of X on Y, we must additionally assume that intervening on X cannot affect the distributions of U, Y, or G, conditional on X as set by the intervention [1] . Inference regarding the causal association between X and Y depends on these assumptions; violations of these assumptions can lead to both false positives or false negatives [2, 3] (see Discussion).
MR has become commonplace in genetic epidemiology, with > 1000 MR studies published since 2005. Most early MR studies were conducted using individual-level data on SNPs, risk factors, and outcomes. These studies used either single SNPs or scores composed of multiple SNP scores as IVs for the exposure. It is now common to use two-sample approaches for MR [4] in which information on the SNPexposure associations and SNP-outcome associations are obtained from different datasets, and these analyses often rely on summary statistics [5] from genome-wide association (GWA) studies. In this review, we summarize MR studies investigating the potential effects of risk factors on cancer risk. We also discuss methodological developments in the area of Mendelian randomization, as well as future directions for MR studies of cancer risk.
Methods for Literature Review
To identify primary research studies using MR to study cancer risk, we conducted a PubMed Search using the search terms "Mendelian randomization" and "cancer" (also using the alternative spelling "Mendelian Randomisation"), restricting to English language articles in peer-reviewed journals. We are aware of several studies that do not use the MR terminology but employ similar methods and draw causal conclusions; therefore, we used the search terms "polygenic risk score" (OR "polygenic score" OR "genetic risk score" OR "genetic score" OR "allele score" OR "allele sum" OR "weighted linear combination") AND "cancer" to identify papers conducting MR-like analyses without explicitly using MR terminology. Our search reflects studies indexed in PubMed as of October 31, 2017 . We read the titles and abstracts of all papers to determine if they were eligible to be included in this review. We classified the MR studies identified according to the type of risk factor studied. All studies we identified are shown in Table 1 . Evidence of an effect was defined as a MR P value < 0.05.
Results

Diet and Lifestyle Factors
Alcohol Consumption
We identified three MR studies examining the effect of alcohol consumption on cancer risk, and all three used a variant at ALDH2 as an IV. These studies provided evidence of an effect of alcohol consumption on increased risk for esophageal [6] , head and neck [7] , and colorectal cancer [8] .
Vitamins D and B12
We identified five MR studies of vitamin D and cancer risk. Most used a set of 3-4 SNPs that are known to associate with circulating vitamin D as IVs, but one study used 8-12 SNPs to construct polygenic scores for tanning, skin color, and freckling as proxies for vitamin D exposure [9] . These studies found no evidence for a causal relationship between vitamin D and colorectal [10] or breast cancer [11] . A large multicancer MR study provided no evidence for a causal effect of MR on risk for prostate, breast, ovarian, colorectal, or lung cancer [12] . However, evidence of a causal relationship between low vitamin D and increased risk was reported for prostate cancer [9] and ovarian cancer [13] . There has been a single study of plasma vitamin B(12) (cobalamin) and total transcobalamin, which focused on prostate cancer [14] ; but this study provided no evidence of a causal relationship.
Fatty Acids
Three MR studies estimated the effect of fatty acid intake on cancer risk, using a set of 1-5 SNPs that predict fatty acid concentrations in blood. Khankarai et al. found no evidence of an overall effect of polyunsaturated fatty acids (PUFA) on prostate cancer risk; however, a potential association for [17] .
Other Dietary Factors
Other dietary factors studied using MR include a study of coffee consumption and prostate cancer [18] and studies of the effect of milk consumption on renal cell carcinoma [19] and overall cancer mortality [20] . In these studies, no evidence of causal relationship was reported.
Anthropometric Traits
BMI/Obesity
We identified 15 MR studies of BMI and cancer risk. These studies used between 1 and 84 SNPs as IVs for BMI. Higher BMI was reported to be associated with increased risk for colorectal [21] [22] [23] ; ovarian [22] , particularly non-high grade serous [24] ; lung [22] , including squamous and small cell carcinoma [25, 26] ; endometrial [27, 28] ; kidney [29] ; gastric [30] ; pancreatic [31] ; and esophageal cancer [32] . Two studies provided evidence of a causal relationship between high BMI and decreased breast cancer risk [22, 33] . A single study provided evidence of an effect of high BMI on decreased risk for lung cancer [29] , but this study was based on a single SNP/IV. No association was shown for prostate cancer [34] or for an "all cancer" phenotype [35] .
Height
We identified six MR studies of height and cancer risk, and these studies used up to 567 SNPs as IVs for height. Evidence of a causal relationship between increasing height and cancer risk was reported for breast [36] , colorectal [37, 38] , and lung cancer [38] . Evidence of a protective effect of height on esophageal adenocarcinoma and Barrett's esophagus was also reported [39] . For prostate and pancreatic cancer, no evidence of a causal relationship was observed [31, 34] .
Other Anthropometric Traits
We identified five MR studies that examined the effect of waist to hip ratio (WHR) on cancer risk. For colorectal cancer, results for WHR were consistent with the BMI results, with both increasing risk [23] . However, studies of endometrial [27] , breast [22] , pancreatic [31] , and lung [26] cancer do not show clear evidence of causal effect. In these studies, results for WHR were often directionally consistent with BMI, suggesting that lack of statistical significance could potentially be due to low power (i.e., weak IVs). Several MR studies also examined birthweight and childhood BMI [22, 23] , with one providing evidence that high childhood BMI decreases breast cancer risk [22] .
Telomere Length
We identified 13 MR studies of telomere length (TL) and cancer risk, and these studies used between 3 and 16 SNPs that predict leukocyte TL as IVs. These studies provided compelling evidence that longer telomeres increase risk for several cancer types, including lung adenocarcinoma [40] [41] [42] , melanoma [42, 43] , renal cell carcinoma [44] , glioma [45] , B-cell lymphoma subtypes [46] , chronic lymphocytic leukemia [47] , as well as neuroblastoma and other childhood cancers [48] .
There was also MR evidence that long TL increases breast cancer risk among Chinese women [49] , but this finding has not yet been observed in studies of women of European ancestry [40, 50•] . A recent paper reported that both longer and shorter telomere length increase risk for HBV-related HCC (i.e., U-shared association) [51] . A recent meta-analysis of MR studies of TL summarized many of the effects reported above [50•] . There are cancer types for which MR studies have not identified such an association, including gastric cancer [52] , as well as prostate, colorectal, ovarian cancer [40, 50•] . This lack of association could be due to either lack of a true effect of TL on those cancer types, a weak effect not detectable using current sample sizes, or poor instruments for tissue-specific TL (IVs obtained from studies of TL in blood cells).
Lipid Traits
We identified eight MR studies of lipid traits and cancer risk, and these studies used between 1 and 67 SNPs as IVs for one or more of the following blood lipid phenotypes: total cholesterol (TC), low-density lipoprotein cholesterol (LDL), highdensity lipoprotein cholesterol (HDL), and triglycerides (TG). Among four studies which used "any cancer" as an outcome, no association was detected for TC [53] or LDL [54] . However, one study reported a relationship between reduced HDL and increased cancer risk [55] , while another identified an inverse relationship for both LDL and TG with cancer risk that the authors attributed to pleiotropy [56] . RodriguezBroadbent et al. [57] reported that higher TG increases colorectal cancer risk (but not LDL or HDL), while Bull et al. reported no association for LDL, HDL, or TG with prostate cancer risk [58] . Carreras-Torres and colleagues observed no effect of various lipid traits on pancreatic cancer [31] , but found evidence of an effect of high LDL on decreased lung cancer risk [26] .
Glycemic Traits
We identified six MR studies of glycemic traits. Three of these studies focused on adiponectin, with two studies reporting no association with colorectal cancer risk [59, 60] and one reporting a positive association with colorectal cancer risk and an inverse association with lung cancer risk [61] . Nead et al. found evidence that higher fasting insulin and postchallenge insulin levels increased endometrial cancer risk, while fasting glucose did not [28] . Studies of pancreatic cancer and lung cancer from Carreras-Torres et al. found evidence that higher fasting insulin increases risk for pancreatic [31] and overall lung cancer [26] .
Inflammation and Infection
We identified five studies of the effect of inflammatory markers/processes on cancer risk. Among these studies, higher IL-10 was linked to increased risk for HPV-and EBV-associated cancers [62] as well as digestive cancers [63] , while high IL-6 was linked to liver cancer [64] . Studies of C-reactive protein (CRP) suggested that increased CRP increases colorectal cancer risk [65] , but did not show an association with overall cancer [66] . A single MR study examined the effect of malarial infection on endemic Burkitt Lymphoma and found evidence that infection increases risk [67] .
Hormonal Factors
We identified four studies of the effects of hormonal factors on hormone-related cancers. Evidence suggested that later age at menopause increases breast cancer risk [68] , while later age at menarche reduces risk of breast and endometrial cancer [69•] . Similarly, MR studies suggested that later age at puberty onset decreases prostate cancer risk [70, 69•] . One MR study of circulating estradiol found that high levels increase endometrial cancer risk [71] .
Other Biomarkers
A variety of circulating biomarkers have been investigated in MR studies of cancer risk, including circulating microRNA miR-34b [72] , plasma fetuin-A [73] , cardiovascular disease marker YKL-40 [74] , insulin-like growth factors [75] , transforming growth factor beta (TGF-beta1) [76] , homocysteine [77] , sRAGE (soluble form of receptor for advanced glycation end products) [78] , and plasma urate [79] . These studies have linked several of these biomarkers to cancer risk (see Table 1 ).
Discussion
Summary
This review of MR studies of cancer risk highlights a number of risk factors likely to have causal relationships with multiple cancer types. The MR-estimated effects of alcohol consumption and obesity on increased risk for multiple cancer types are largely consistent with observational studies. In contrast, the MR evidence supporting an effect of vitamin D on cancer risk is rather weak, despite associations observed in prior observational studies [80] . The estimated effect of longer TL on increased risk for multiple cancers is contradictory to numerous prior observational studies which suggested that short TL increases cancer risk. This highlights the limitations of these prior studies, including non-prospective TL measurement [81, 82] . This review also highlights the need to study specific cancer types, ideally subtypes, as the effects of risk factors can be heterogeneous across cancer types. Studying an "all cancer" phenotype will mask such heterogeneous effects.
Statistical Power for MR
The primary determinants of power for MR studies are sample size, instrument strength, and effect size (of the risk factor on cancer risk) [83] [84] [85] . Using a larger number of SNPs in the context of a SNP/allele score can increase IV strength, thereby increasing power/precision [83, 86, 87] , although most genetic IVs explain < 5% of the variability of the risk factor. Very recent MR studies tend to use larger sample sizes and more SNPs/IVs (Table 1) , and this is because the sample sizes of cancer GWA studies are increasing (i.e., the typical data source for MR studies) and new SNPs that affect risk factors of interest are being discovered over time, providing more IVs for MR. Consequently, recent studies tend to provide stronger evidence, in terms of both the precision of MR estimates, as well as the number of SNP/IVs that can potentially provide complementary evidence supporting an effect or lack thereof. For some MR studies, very weak effects of risk factors on cancer may be present (a parameter which investigators cannot control), so we must keep in mind that a null result does not rule out the existence of an effect too weak to be detected.
MR Study Design
Many recent MR studies use two-sample approaches [4] and MR methods that utilize SNP summary statistics [5] , which can enable highly efficient MR study designs while boosting sample size. For two-sample approaches, SNP-risk factor associations and SNP-cancer associations are obtained from different datasets (ideally from the same source population). This allows one to use large samples from existing GWA studies, rather than collect risk factor and outcome data on a single sample. Furthermore, MR methods that use summary statistics enable the use of meta-analysis of results from multiple individual studies and avoid the need for individual-level data. These developments enable larger, more powerful studies to be conducted in a highly efficient manner for large numbers of cancer risk factors. However, bias can arise in the two-sample setting when the samples share common participants [88] .
Violations of MR Assumptions and Sensitivity Analyses
Many of the very recent MR studies reported here have used newly developed approaches for sensitivity analyses that assess potential violations of MR assumptions (described in the Introduction) using SNP summary statistics. This includes Egger regression [89•] as well as weighted median estimators [90] for obtaining MR estimates that are robust to pleiotropy (under some assumptions). In addition, methods have been developed for individual-level (i.e., one-sample) data that estimate effects for multiple interrelated exposures and allow for analysis of mediation [91, 92] . While MR research is currently shifting to two-sample approaches that use summary statistics to increase power, individual-level one-sample data may prove useful for mediation and multivariate analyses, as well as validation of MR assumptions [93] . However, weak IV bias is a more prominent concern for one-sample as compared to two-sample MR analyses [5] . Violations of MR assumptions may be of particular concern for MR studies of the effect of molecular/cellular phenotypes on cancer risk. Most recent MR studies use IVs with well-validated associations with the risk factor in interest (X). However, this assumption might be concern with "transcriptome-wide association studies," where X is (tissuespecific) gene expression. In such studies, liberal significance thresholds and small sample sizes for identifying eQTLs (expression quantitative trait loci) may lead to false-positive associations between the IVs (G 1 ,…, G n ) and X [94] [95] [96] . Absence of a true association between the IV(s) and X makes any inference about the X-Y relationship impossible. In addition, the "exclusion restriction" assumption-that the genetic IV (s) have no association with Y conditional on X-can be violated by pleiotropy or co-localization due to linkage disequilibrium. Under pleiotropy, the IV(s) is/are causally related to Y through a causal pathway that is not mediated by X. Under co-localization, the IV(s) may not be causally related to Y (except perhaps through X), but they are in linkage disequilibrium with other variants that are causally related to Y through a mechanism that does not involve X. This is also a concern for transcriptome-wide association studies, as eQTLs for different genes often co-localize. Methods to alleviate concerns regarding violations of MR assumptions are currently an active area of investigation [3] .
Future Directions
In the coming years, MR is likely to become an increasingly powerful tool for understanding cancer causation. GWA studies of cancer risk factors will identify new variants that can be used as IVs, increasing power for MR and enabling additional risk factors to be studied. GWA studies of cancer risk will continue to increase in size and focus on cancer subtypes, and the availability of summary statistics from these studies will enable powerful MR studies that are subtype-specific. Furthermore, tissue-and cell type-specific studies of molecular QTLs (quantitative trait loci), such as expression QTLs, DNA methylation QTLs, and protein QTLs, will enable genetic prediction of tissue-specific molecular phenotypes, enabling MR-like studies of cell type-specific molecular phenotypes [94] [95] [96] [97] [98] .
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